Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAMSAClax trial of venetoclax added to FLAMSA + treosulfan conditioning before allogeneic stem cell transplantation
2022-002435-66Phase 2Active
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: Safety through day +30 after transplantation. Started Oct 2022; status: active.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2022-002435-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002435-66.